A clinical-stage biopharmaceutical company developing a differentiated FGF21 for NASH and SHTG

NASDAQ: XXXX

$18.00 +0.3 (+1.69%)

Copyright West LLC.
Minimum 15 minutes delayed.

Press Releases

09/25/2019

89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent

08/08/2019

89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH

05/22/2019

89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100, an Investigational Medicine for NASH